Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Travoprost APS 40 micrograms/ml eye · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| Travoprost APS | EXPERIMENTAL | Travoprost APS 40 micrograms/ml eye drop solution, 1 drop in the study eye(s), once daily each evening, for 90 days |
| XALATAN | ACTIVE_COMPARATOR | Latanoprost 50 micrograms/ml eye drop solution, 1 drop in the study eye(s), once daily each evening, for 90 days |
| Name | Type | Description |
|---|---|---|
| Travoprost APS 40 micrograms/ml eye drop solution | DRUG | non-BAK (benzalkonium chloride) medication |
| Latanoprost 50 micrograms/ml eye drop solution | DRUG | BAK-preserved medication |
Inclusion Criteria: * Must have a clinical diagnosis of open-angle glaucoma (with or without pseudoexfoliation or pigment dispersion component), or ocular hypertension in at least 1 eye. * Must be willing and able to discontinue use of any topical ocular medication other than the study medication f...
Top 3 of 5 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Glaukos Corp | GKOS | 3 | PHASE4 | Travoprost Intraocular, high elution |
| Amneal Pharmaceuticals, Inc. Class A | AMRX | 1 | PHASE4 | Bimatoprost ophthalmic solution |
| AbbVie, Inc. | ABBV | 1 | PHASE4 | bimatoprost |
Travoprost APS 40 micrograms/ml eye is an ophthalmic solution being developed for open angle glaucoma and ocular hypertension. It is a small molecule therapy delivered as an eye drop. The Phase 3 program studied it in adults 18 years and older with these conditions.
Travoprost APS 40 micrograms/ml eye targets PTGFR, the prostaglandin F receptor, and acts as an agonist. By activating this receptor, the compound is designed to influence aqueous humor dynamics relevant to lowering intraocular pressure in glaucoma. PTGFR agonism is the established mechanism for this drug class.
Travoprost APS 40 micrograms/ml eye is developed by Alcon Inc., which trades under the ticker ALC. Alcon is an ophthalmology-focused pharmaceutical company, and this asset sits within its glaucoma portfolio. The company sponsored the Phase 3 study evaluating the formulation.
Travoprost APS 40 micrograms/ml eye is in Phase 3 development. It is an investigational product and is not approved for commercial use. The single registered Phase 3 trial has been completed, and no trials are currently listed as active.
Travoprost APS 40 micrograms/ml eye was evaluated in one completed Phase 3 trial, NCT00892762, titled Travoprost APS Versus Xalatan in Patient Reported Outcomes and Ocular Surface Health. The study enrolled 434 adults with open angle glaucoma or ocular hypertension and used a randomized, double-blind, active-controlled design.